A new best practice pathway for the use of non-oral treatments in Parkinson’s has been devised by clinicians to make the referral process for these therapies more explicit.
The new guideline pathway, for the first time, gives clinicians a road-map for the use of non-oral therapy (apomorphine, intestinal levodopa gel infusion[Duodopa]and deep brain stimulation).
The tool will help clinicians understand referral criteria and the local process for referral. The framework has been developed with the guidance of a steering group of movement disorder specialists, clinicians from the UK Parkinson’s Excellence Network and neurological services commissioners. Information on the non-oral treatment care pathway for Parkinson’s can be accessed at: www.parkinsons.org.uk/nonoralpathway
